Targeting BMI-1 with PLGA–PEG nanoparticle-containing PTC209 modulates the behavior of human glioblastoma stem cells and cancer cells

Abstract Despite advances in glioblastoma (GBM) treatments, current approaches have failed to improve the overall survival of patients. The oncogene BMI-1, a core member polycomb group proteins, is potential novel therapeutic target for GBM. To enhance efficacy and reduce toxicity, PTC209, BMI-1 inhibitor, was loaded into PLGA–PEG nanoparticle conjugated with CD133 antibody (Nano-PTC209) its effect on behavior human GBM stem-like cells (GSCs) cell line (U87MG) assessed. Nano-PTC209 has diameter ~ 75 nm efficient drug loading controlled release. IC50 values GSCs U87MG were considerably lower than PTC209. significantly decreased viability both dose-dependent manner caused significant enhancement apoptosis p53 levels as well inhibition AKT JNK signaling pathways. Furthermore, inhibited migration ability, activity metalloproteinase-2 -9, increased generation reactive oxygen species cells. Our data indicate that could be an ideal nanocarrier deliver PTC209 effectively treatment